​

Regenerelle™, LLC, was founded in 2020 with a desire to advance the state of regenerative medicine. Within a year of its inception, Regenerelle designed and started operations in an ISO Class 7 compliant clean room facility, conceptualized and launched a suite of Wharton’s jelly products, developed an extensive product pipeline across a range of clinical applications, and established a portfolio of intellectual property. Regenerelle™  portfolio of products includes, WJ-MSCs, EVs and growth media.

 

These groundbreaking products apply to a wide range of clinical applications and provide a foundation on which Regenerelle™ is developing new regenerative technologies at the intersection of pharmaceuticals, medical devices, and human cell and tissue applications.

​